A Phase 1 Study of LY2606368 in Japanese Patients with Advanced Solid Tumors

Eli Lilly Japan K.K.0 个研究点开始时间: 2015年9月9日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•Participant must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed
•Participant must have diagnosis of cancer that is advanced or metastatic
•Participant must have discontinued previous treatments for cancer and recovered from the acute effects of that therapy
•If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug
•If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding
•Participant must not have symptomatic central nervous system malignancy or metastasis
•Participant must not have current hematologic malignancy
•Participant must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C
•Participant must not have a serious cardiac condition

发起方